Influence of the alkylating function of aldo-Ifosfamide on the anti-tumor activityVoelcker, GeorgAnti-Cancer Drugs: January 2018 - Volume 29 - Issue 1 - p 75–79 doi: 10.1097/CAD.0000000000000569 Preclinical Reports Abstract Author Information The present work investigates the influence of different DNA damages caused by different isophosphoramide mustards on the 3-hydroxypropanal-assisted apoptotic antitumor activity of oxazaphosphorine cytostatics using I-aldophosphamide-perhydrothiazine (IAP) and mesyl-I-aldophosphamide-perhydrothiazine (SUM-IAP) for in-vitro and in-vivo experiments. IAP and SUM-IAP hydrolyze spontaneously to the corresponding I-aldophosphamide derivatives. They differ in the chemical structure of the alkylating moiety, whereas IAP has two chlorethyl groups in the SUM-IAP molecule, one chlorethyl group is substituted by a mesylethyl group. With both substances, cytotoxicity studies on P388 tumor cells in vitro and therapy experiments in mice bearing advanced growing P388 tumors were carried out. IAP was significantly more cytotoxic in-vitro than SUM-IAP, but the antitumor activity of SUM-IAP was by order of magnitude higher than the antitumor activity of IAP. The reason for these findings is discussed with respect to the enzymatic cleavage of the various I-aldophosphamide derivatives to the corresponding isophosphoramide mustards and 3-hydroxypropanal. Overall, the findings indicate that antitumor activity of ifosfamide and derivatives of ifosfamide can be improved considerably by altering the alkylating moiety of the molecule, but retaining the aldophosphamide structure. Institute of Biochemistry II, Goethe University Frankfurt Medical School, Frankfurt, Germany Correspondence to Georg Voelcker, PhD, Institute of Biochemistry II, Goethe University Frankfurt Medical School, Geb. 75, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany Tel: +49 69 6301 5652; fax: +49 69 6301 5577; e-mails: email@example.com, firstname.lastname@example.org Received March 31, 2017 Accepted September 13, 2017 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.